Depression in patients with schizophrenia during an acute psychotic episode.

Compr Psychiatry

Veterans Affairs Puget Sound Health Care System, University of Washington, Tacoma, WA 98493, USA.

Published: October 2001

There is disagreement about whether depressive symptoms in schizophrenia are part of the basic disease process, or whether they represent adverse effects of treatment with antipsychotic medications. In a sample of initially antipsychotic drug-free acutely hospitalized patients with schizophrenia (N = 104), we measured change in depressive symptoms after 4 weeks of treatment. We also examined the relationship of changes in depressive symptoms to changes in positive and negative schizophrenic symptoms. Depressive symptoms improved after 4 weeks of antipsychotic medication treatment, and their improvement corresponded with improvement in both positive and negative schizophrenic symptoms. These results suggest that depressive symptoms in schizophrenia are related to the disease process itself, at least during acute exacerbations of schizophrenia. Depressive symptoms may be responsive to antipsychotic medications directly or as a secondary response to improvement in positive and negative symptoms.

Download full-text PDF

Source
http://dx.doi.org/10.1053/comp.2001.24577DOI Listing

Publication Analysis

Top Keywords

depressive symptoms
24
positive negative
12
symptoms
9
patients schizophrenia
8
symptoms schizophrenia
8
disease process
8
antipsychotic medications
8
negative schizophrenic
8
schizophrenic symptoms
8
symptoms depressive
8

Similar Publications

Voice Quality as Digital Biomarker in Bipolar Disorder: A Systematic Review.

J Voice

January 2025

Department of Surgery, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium; Division of Laryngology and Bronchoesophagology, Department of Otolaryngology Head Neck Surgery, EpiCURA Hospital, Baudour, Belgium; Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France; Department of Otolaryngology, Elsan Hospital, Paris, France. Electronic address:

Background: Voice analysis has emerged as a potential biomarker for mood state detection and monitoring in bipolar disorder (BD). The systematic review aimed to summarize the evidence for voice analysis applications in BD, examining (1) the predictive validity of voice quality outcomes for mood state detection, and (2) the correlation between voice parameters and clinical symptom scales.

Methods: A PubMed, Scopus, and Cochrane Library search was carried out by two investigators for publications investigating voice quality in BD according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.

View Article and Find Full Text PDF

The Clinical Neuroscience of Lucid Dreaming.

Neurosci Biobehav Rev

January 2025

Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.

During most dreams, the dreamer does not realize that they are in a dream. In contrast, lucid dreaming allows to become aware of the current state of mind, often accompanied by considerable control over the ongoing dream episode. Lucid dreams can happen spontaneously or be induced through diverse behavioural, cognitive or technological strategies.

View Article and Find Full Text PDF

Background: Major depressive disorder (MDD) comes along with an increased risk of recurrence and poor course of illness. Machine learning has recently shown promise in the prediction of mental illness, yet models aiming to predict MDD course are still rare and do not quantify the predictive value of established MDD recurrence risk factors.

Methods: We analyzed N = 571 MDD patients from the Marburg-Münster Affective Disorder Cohort Study (MACS).

View Article and Find Full Text PDF

A prospective study of the association between lifestyle and the risk of depressive symptoms.

J Affect Disord

January 2025

Department of Epidemiology, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima 960-1295, Japan; Radiation Medical Science Center for the Fukushima Health Management Survey, Fukushima Medical University, 1 Hikariga-oka, Fukushima 960-1295, Japan. Electronic address:

Background: Few studies have prospectively, comprehensively, and by sex, examined the relationship between lifestyle and depressive symptoms. This study aimed to longitudinally examine which lifestyle factors are associated with depressive symptoms in a large cohort of Japanese participants stratified by sex.

Methods: Among 9087 office and community-based residents who attended a health measurement course at the Osaka Medical Center for Health Science and Promotion between 2001 and 2002, 6629 individuals (3962 men and 2667 women) without prior depressive symptoms were followed until the end of March 2012 to observe the associations between lifestyle factors and the development of new depressive symptoms.

View Article and Find Full Text PDF

Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this exploratory study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive-Behavioral Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!